会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明公开
    • 인간 인터페론 알파의 발현 분비벡터 및 이를 이용한인터페론 알파의 생산 방법
    • 表达人体干扰素的表达载体和使用其的人间干细胞生产方法
    • KR1020010073658A
    • 2001-08-01
    • KR1020000002434
    • 2000-01-19
    • 한미사이언스 주식회사
    • 권세창정성엽최기두김차순배성민이관순
    • C12N15/21
    • C07K14/245C07K14/56C07K2319/02C12N15/70
    • PURPOSE: The expression vectors expressing human interferon alpha and a method for producing human interferon alpha using the same vectors are provided, thereby the interferon alpha having the same amino acid sequence as that of natural interferon alpha can be mass produced using E. coli. CONSTITUTION: The expression vector contains the gene encoding the modified thermostable enterotoxin II sequence, in which at least one of amino acids among 4th, 20th and 22th amino acids of normal thermostable enterotoxin II sequence represented by the sequence ID. No. 3 is substituted by other amino acids such as threonine, glutamine or valine, and the human interferon alpha gene linked at 3'-terminal of the modified thermostable enterotoxin II sequence. The human interferon alpha is produced by incubating microorganisms transformed with the expression vectors under the appropriate conditions.
    • 目的:提供表达人干扰素α的表达载体和使用相同载体产生人干扰素α的方法,由此可以使用大肠杆菌大量生产具有与天然干扰素α相同的氨基酸序列的干扰素α。 构成:表达载体含有编码经修饰的耐热肠毒素II序列的基因,其中由序列ID表示的正常耐热性肠毒素II序列的第4位,第20位和第22位氨基酸中的至少一个氨基酸。 3号被其他氨基酸如苏氨酸,谷氨酰胺或缬氨酸取代,而人干扰素α基因在修饰的热稳定性肠毒素II序列的3'-末端连接。 通过在合适的条件下温育用表达载体转化的微生物来产生人类干扰素α。
    • 4. 发明公开
    • 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
    • 人造粒菌群刺激因子变异及其生产方法
    • KR1020010009171A
    • 2001-02-05
    • KR1019990027418
    • 1999-07-08
    • 한미사이언스 주식회사
    • 권세창정성엽최기두김차순최재도이관순
    • C12N15/70C12N15/12
    • C07K14/535C07K2319/034C07K2319/75C12N15/625C12N15/70
    • PURPOSE: Provided are a human granulocyte-colony stimulating factor (hG-CSF) variant, a DNA encoding it, an expression vector comprising the DNA and a cell line transformed with the expression vector. The hG-CSF variant has high expression efficiencies, in case of expressing with a secretory sequence, it has an excellent secretion rate. Also, methionine free hG-CSF at its amino terminal or the variant thereof can be produced in large scale by secreting into periplasm . CONSTITUTION: The hG-CSF variant has one or more amino acids that is substituent of 1st, 2nd, 3rd and 17th amino acids of nature hG-CSF having an amino acid sequence of SEQ ID NO : 2 substituted, with other amino acids. Preferably, the variant has independently Thr1 and Cys17 substituted with Ser, Pro2 substituted with Met and Leu3 substituted with Val. The producing method of the hG-CSF variant comprises the steps of : transforming E. coli with an expression vector comprising a gene encoding hG-CSF or the variant thereof and a secretory sequence gene linked to 5'-end thereof; culturing the transformed E. coli under suitable condition to secrete the methionine free hG-CSF variant into the periplasm. The secretory sequence gene is E. coli-derived thermal-stable enterotoxin secretory sequence.
    • 目的:提供人粒细胞集落刺激因子(hG-CSF)变体,编码它的DNA,包含DNA和表达载体转化的细胞系的表达载体。 hG-CSF变体具有高表达效率,在用分泌序列表达的情况下,具有优异的分泌速率。 此外,其氨基末端的甲硫氨酸游离hG-CSF或其变体可以通过分泌到周质中而大量生产。 构成:hG-CSF变体具有一个或多个氨基酸,其是具有SEQ ID NO:2的氨基酸序列与其它氨基酸取代的天然hG-CSF的第1,第2,第3和第17氨基酸的取代基。 优选地,所述变体独立地被Ser1取代的Thr1和Cys17,被Met取代的Pro2和被Val取代的Leu3。 hG-CSF变体的制备方法包括以下步骤:用包含编码hG-CSF或其变体的基因的表达载体和与其5'末端连接的分泌序列基因转化大肠杆菌; 在合适的条件下培养转化的大肠杆菌以将无甲硫氨酸的hG-CSF变体分泌到周质中。 分泌序列基因是大肠杆菌来源的热稳定肠毒素分泌序列。